Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
JSW Infrastructure (NSE: JSWINFRA) targets Rs 7,503cr institutional raise for ports, logistics and debt reduction
JSW Infrastructure’s ₹7,503 crore QIP backs port expansion, logistics and debt reduction. Find out if growth can outweigh #JSWINFRA dilution. Read more now.
Eli Lilly (LLY) drug access strategy puts pricing, Medicare and GLP-1 growth in focus
Find out how Eli Lilly’s drug access strategy could reshape LLY stock, GLP-1 pricing, Medicare coverage and pharma competition.
Guardian Pharmacy’s quiet leadership reshuffle could shape GRDN’s next growth phase
Discover why Guardian Pharmacy Services’ COO and CFO succession could shape operations, margins and GRDN’s next growth phase. Read the full analysis now.
Legend Biotech (NASDAQ: LEGN) CARVYKTI scaling meets LB2102 solid tumor signal
Legend Biotech (NASDAQ: LEGN) printed 62% CARVYKTI growth and a solid tumor CAR-T signal. The 2026 profitability target is the next real test.
Why Chicago’s bloody holiday weekend could hand Trump a new crime-fight opening
Find out how Chicago’s deadly Juneteenth weekend shootings could reshape the debate over crime, policing and federal intervention today!
Avacta targets late-2026 AVA6103 data as AVCT shifts from funding risk to clinical proof
Avacta Group has outlined a catalyst-heavy second half of 2026, with new AVA6000 data, the first AVA6103 clinical results and potential partnering decisions set to test the commercial value of its tumour-activated oncology platform.
Jazz Pharmaceuticals (JAZZ) builds $4bn oncology option through AbCellera partnership
Jazz could pay AbCellera more than $4 billion across five oncology programmes. Read how the option deal reshapes JAZZ and ABCL growth strategies.
Nuvectis (NVCT) licenses two Haisco drugs as $1.46bn deal transforms its pipeline
Nuvectis licenses two Haisco drugs in a deal worth up to $1.46 billion. Find out how financing risk could reshape NVCT’s pipeline and investor outlook next.
AbbVie weighs $10.9bn Apogee deal to strengthen its next immunology growth cycle
AbbVie may pay $10.9 billion for Apogee Therapeutics before Phase 3. Read what the reported deal could mean for immunology growth and ABBV stock.
The factory is 60% empty. That may be exactly why Aurobindo Pharma (NSE: AUROPHARMA) wants it
Read how Aurobindo Pharma plans to turn Lannett’s underused US factory, ADHD portfolio and CDMO platform into its next growth engine as policy shifts.